Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Moderna reported third-quarter 2025 revenue of $1 billion, primarily driven by the sales of its vaccines, Spikevax, mNEXSPIKE, and mRESVIA.</li><li>The company posted a net loss of $200 million for the quarter.</li><li>Moderna’s financial position remains robust, with $6.6 billion in cash and investments.</li></ul>

Moderna reported third-quarter 2025 revenue of $1 billion, primarily driven by the sales of its vaccines, Spikevax, mNEXSPIKE, and mRESVIA.The company posted a net loss of $200 million for the quarter.Moderna’s financial position remains robust, with $6.6 billion in cash and investments.

Moderna Builds a Diversified Biotech Powerhouse — And Its Next Growth Cycle Is Already Forming!

<ul><li>During the third quarter of 2025, Moderna Inc. reported $1 billion in revenue, primarily driven by sales of their approved vaccines: Spikevax, mNEXSPIKE, and mRESVIA.</li><li>However, the company reported a net loss of $200 million, contrasting with a profit of $13 million in the same period the previous year.</li><li>The decline in revenue, by 45% year-over-year, was mainly due to reduced demand for COVID vaccines.</li></ul>

During the third quarter of 2025, Moderna Inc. reported $1 billion in revenue, primarily driven by sales of their approved vaccines: Spikevax, mNEXSPIKE, and mRESVIA.However, the company reported a net loss of $200 million, contrasting with a profit of $13 million in the same period the previous year.The decline in revenue, by 45% year-over-year, was mainly due to reduced demand for COVID vaccines.

Moderna In Crisis? FDA Memo Ties Vaccines To Deaths, Stock Tumbles!

<ul><li>The earnings report for Moderna, Inc.'s second quarter of 2025 presents a multifaceted picture of the company's current financial health and strategic endeavors.</li><li>Beginning with the financial landscape, Moderna reported revenues of $2.1 billion and experienced a loss of $0.8 billion, which aligns with the company's expectations given the seasonal nature of its respiratory vaccine business.</li><li>Notably, the company managed to reduce its cost of sales and SG&A by 35% compared to the previous year, indicating a strong commitment to financial discipline.</li></ul>

The earnings report for Moderna, Inc.'s second quarter of 2025 presents a multifaceted picture of the company's current financial health and strategic endeavors.Beginning with the financial landscape, Moderna reported revenues of $2.1 billion and experienced a loss of $0.8 billion, which aligns with the company's expectations given the seasonal nature of its respiratory vaccine business.Notably, the company managed to reduce its cost of sales and SG&A by 35% compared to the previous year, indicating a strong commitment to financial discipline.

Moderna’s Mysterious Exit Sparks Acquisition Frenzy—What’s Really Happening?

Moderna Inc Expands Beyond Respiratory Vaccines – Is Diversification the Key to Long-Term Success?

<ul><li>Moderna's recent earnings revealed several significant developments affecting its financial and strategic outlook.</li><li>First-quarter 2025 revenues stood at $0.1 billion, with a net loss of $1 billion.</li><li>Despite this loss, it was in line with company expectations, reflecting the seasonal nature of its respiratory vaccine business.</li></ul>

Moderna's recent earnings revealed several significant developments affecting its financial and strategic outlook.First-quarter 2025 revenues stood at $0.1 billion, with a net loss of $1 billion.Despite this loss, it was in line with company expectations, reflecting the seasonal nature of its respiratory vaccine business.

Moderna Inc.: Will Its Oncology Innovations & Pipeline Expansion Become The MUCH NEEDED Breakthrough After The Covid Vaccine?

United States

Moderna, Inc. operates as a biotechnology company. The Company focuses on the discovery and development of messenger RNA therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Moderna (MRNA US)

Moderna Builds a Diversified Biotech Powerhouse — And Its Next Growth Cycle Is Already Forming!

Moderna reported third-quarter 2025 revenue of $1 billion, primarily driven by the sales of its vaccines, Spikevax, mNEXSPIKE, and mRESVIA. The...

Baptista Research

Moderna In Crisis? FDA Memo Ties Vaccines To Deaths, Stock Tumbles!

During the third quarter of 2025, Moderna Inc. reported $1 billion in revenue, primarily driven by sales of their approved vaccines: Spikevax,...

Baptista Research

Moderna’s Mysterious Exit Sparks Acquisition Frenzy—What’s Really Happening?

The earnings report for Moderna, Inc.'s second quarter of 2025 presents a multifaceted picture of the company's current financial health and...

Baptista Research

Moderna Inc Expands Beyond Respiratory Vaccines – Is Diversification the Key to Long-Term Success?

The earnings report for Moderna, Inc.'s second quarter of 2025 presents a multifaceted picture of the company's current financial health and...

Baptista Research

Moderna Inc.: Will Its Oncology Innovations & Pipeline Expansion Become The MUCH NEEDED Breakthrough After The Covid Vaccine?

Moderna's recent earnings revealed several significant developments affecting its financial and strategic outlook. First-quarter 2025 revenues...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)